A demonstration project implementing extended-release naltrexone in Los Angeles County

References

• National Quality Forum (NQF). National voluntary consensus standards for the treatment of substance use conditions: evidence-based treatment practices. Paper presented at The National Quality Forum; 2007; Washington, DC.
   Google Scholar
• World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: World Health Organization; 2009.
   Google Scholar
• Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491–503.
   PubMed Web of Science ®Google Scholar
• Kleber HD. Naltrexone. J Subst Abuse Treat. 1985;2:117–122.
   PubMedGoogle Scholar
• Kovas AE, McFarland BH, McCarty DJ, Boverman JF, Thayer JA. Buprenorphine for acute heroin detoxification: diffusion of research into practice. J Subst Abuse Treat. 2007;32:199–206.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR. Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction. 2008;103:1801–1808.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5:21–27.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat. 2006;30:363–373.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM. The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment. J Health Soc Behav. 2007;48:195–210.
   PubMed Web of Science ®Google Scholar
• Rieckmann T, Kovas AE, Rutkowski BA. Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities. J Psychoactive Drugs. 2010;(Suppl 6):227–238.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2010. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
   Google Scholar
• Abraham AJ, Knudsen HK, Rieckmann T, Roman PM. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. J Stud Alcohol Drugs. 2013;74:258–265.
   PubMed Web of Science ®Google Scholar
• Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584–589.
   PubMed Web of Science ®Google Scholar
• Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51:635–646.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Roman PM. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs. 2010;71:460–466.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Incorporating Alcohol Pharmacotherapies Into Medical Practice. Treatment Improvement Protocol (TIP) Series 49. In: Treatment. CfSA, ed. Rockville, MD: xxx; 2009.
   Google Scholar
• Thomas CP, Garnick DW, Horgan CM, et al. Advancing performance measures for use of medications in substance abuse treatment. J Subst Abuse Treat. 2011;40:35–43.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Abraham AJ, Oser CB. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval Program Plann. 2011;34:375–381.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Rieckmann T, McNulty T, Kovas AE, Roman PM. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav. 2011;36:576–583.
   PubMed Web of Science ®Google Scholar
• Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. J Subst Abuse Treat. 2011;41:374–385.
   PubMed Web of Science ®Google Scholar
• Pinto RM, Yu G, Spector AY, Gorroochurn P, McCarty D. Substance abuse treatment providers' involvement in research is associated with willingness to use findings in practice. J Subst Abuse Treat. 2010;39:188–194.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves injectable drug to treat opioid-dependent patients. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229109.htm. Published 2010. Accessed September 29, 2012.
   Google Scholar
• Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–218.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep. 2006;8:383–388.
   PubMedGoogle Scholar
• Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM. Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry. 2008;69:190–195.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617–1625.
   PubMed Web of Science ®Google Scholar
• Lee JD, Grossman E, DiRocco D, et al. Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat. 2010;39:14–21.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167:668–675.
   PubMed Web of Science ®Google Scholar
• Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci. 2001;21:5916–5924.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother. 2007;7:1265–1277.
   PubMedGoogle Scholar
• Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res. 2009;33:350–356.
   PubMed Web of Science ®Google Scholar
• O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007;27:507–512.
   PubMed Web of Science ®Google Scholar
• Lukas SE, Lowen SB, Lindsey KP, et al. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. NeuroImage. 2013;78:176–185.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108:1628–1637.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Mariani JJ, et al. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend. 2013;133:80–85.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71–83.
   PubMed Web of Science ®Google Scholar
• Crevecoeur-MacPhail D, Ransom L, Myers AC, et al. Inside the black box: measuring addiction treatment services and their relation to outcomes. J Psychoactive Drugs. 2010;42(Suppl 6):269–276.
   Google Scholar
• Coviello DM, Cornish JW, Lynch KG, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33:48–59.
   PubMed Web of Science ®Google Scholar
• Collins SE, Duncan MH, Smart BF, et al. Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence. Subst Abus. 2015; 2:36(1):21–33
   Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. 2011 State Profile — California National Survey of Substance Abuse Treatment Services (N-SSATS). Substance Abuse and Mental Health Services Administration; 2011.
   Google Scholar
• Capone T, Brahen L, Condren R, Kordal N, Melchionda R, Peterson M. Retention and outcome in a narcotic antagonist treatment program. J Clin Psychol. 1986;42:825–833.
   PubMed Web of Science ®Google Scholar
• Greenstein RA, Evans BD, McLellan AT, O'Brien CP. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend. 1983;12:173–180.
   PubMed Web of Science ®Google Scholar